ELDN
Eledon Pharmaceuticals, Inc.
Price Chart
Latest Quote
$3.92
+0.22 (+5.95%)
Current Price
| Previous Close | $3.70 |
| Open | $3.78 |
| Day High | $3.96 |
| Day Low | $3.75 |
| Volume | 2,640,353 |
Stock Information
| Shares Outstanding | 77.19M |
| Total Debt | $555K |
| Cash Equivalents | $111.09M |
| Net Income | $-78.15M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $302.58M |
| EPS (TTM) | $-0.77 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $192.04M |
| Income | $-78.15M |
| Book/sh | $1.32 |
| Cash/sh | $1.44 |
| Employees | 33 |
Financial Ratios
| Quick Ratio | 8.30 |
| Current Ratio | 8.44 |
| Debt/Eq | 0.55 |
Returns & Margins
| ROA | -35.09% |
| ROE | -72.68% |
Ownership
| Insider Ownership | 1.09% |
| Institutional Ownership | 59.23% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.42 |
| P/B | 2.97 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $8.20 |
Technical Indicators
| SMA20 | $3.67 |
| SMA50 | $3.66 |
| SMA200 | $2.73 |
| RSI | 53.33 |
| ATR | 0.2307 |
| Shares Float | 69.93M |
| Short Float | 9.44% |
| Short Ratio | 6.44 |
| Volatility | 0.97 |
| Rel Volume | 2.48 |
Performance History
| Week | +9.80% |
| Month | +9.50% |
| Quarter | +37.54% |
| 6 Months | +140.49% |
| YTD | +141.98% |
| Year | +39.50% |
| 3 Years | +120.22% |
| 5 Years | -55.40% |
| 10 Years | -99.60% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $3.92 | 2,640,400 |
| 2026-06-17 | $3.70 | 1,485,400 |
| 2026-06-16 | $3.48 | 574,400 |
| 2026-06-15 | $3.43 | 958,900 |
| 2026-06-12 | $3.57 | 1,314,000 |
| 2026-06-11 | $3.57 | 767,700 |
| 2026-06-10 | $3.46 | 754,200 |
| 2026-06-09 | $3.55 | 1,217,500 |
| 2026-06-08 | $3.58 | 1,829,500 |
| 2026-06-05 | $3.41 | 757,800 |
| 2026-06-04 | $3.60 | 617,000 |
| 2026-06-03 | $3.49 | 1,063,000 |
| 2026-06-02 | $3.53 | 950,700 |
| 2026-06-01 | $3.76 | 900,200 |
| 2026-05-29 | $3.81 | 794,600 |
| 2026-05-28 | $3.87 | 681,600 |
| 2026-05-27 | $3.90 | 963,500 |
| 2026-05-26 | $3.89 | 1,419,100 |
| 2026-05-22 | $3.89 | 666,500 |
| 2026-05-21 | $3.89 | 928,300 |
| 2026-05-20 | $3.84 | 917,700 |
| 2026-05-19 | $3.58 | 873,200 |
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
đ° Latest News
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2026-06-16T13:40:02Z
Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart
Insider Monkey âĸ 2026-06-10T18:22:50Z
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-05-29T13:40:03Z
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
Benzinga âĸ 2026-05-01T20:00:52Z
Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money
Insider Monkey âĸ 2026-04-20T14:14:54Z
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference
MarketBeat âĸ 2026-03-15T18:31:50Z
NewcelX and Eledon partner for NCEL-101 programme
Hospital Management âĸ 2026-03-10T10:53:47Z
Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for âTegoâ at Conference
MarketBeat âĸ 2026-02-13T17:34:00Z
Assessing Eledon Pharmaceuticals (ELDN) Valuation After Phase 2 Kidney Transplant Trial Results and Phase 3 Prospects
Simply Wall St. âĸ 2025-11-10T03:15:40Z
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is largely controlled by institutional shareholders who own 51% of the company
Simply Wall St. âĸ 2025-10-09T12:08:47Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $83,251,000 | $70,577,000 | $43,000,000 | $39,780,000 |
| Other Income Expense | $37,669,000 | $34,824,000 | $-73,537,000 | $-48,186,000 |
| Other Non Operating Income Expenses | $4,220,000 | $3,924,000 | $2,674,000 | $462,000 |
| Operating Expense | $83,251,000 | $70,577,000 | $43,000,000 | $39,780,000 |
| General And Administrative Expense | $16,984,000 | $18,613,000 | $12,688,000 | $12,700,000 |
| Net Non Operating Interest Income Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-45,617,000 | $-36,184,000 | $-116,537,000 | $-87,966,000 |
| Normalized Income | $-72,041,710 | $-60,595,000 | $-40,326,000 | $-39,318,000 |
| Net Income From Continuing And Discontinued Operation | $-45,617,000 | $-36,184,000 | $-116,537,000 | $-87,966,000 |
| Net Income Common Stockholders | $-45,617,000 | $-36,184,000 | $-116,537,000 | $-87,966,000 |
| Net Income | $-45,617,000 | $-36,184,000 | $-116,537,000 | $-87,966,000 |
| Net Income Including Noncontrolling Interests | $-45,617,000 | $-36,184,000 | $-116,537,000 | $-87,966,000 |
| Net Income Continuous Operations | $-45,617,000 | $-36,184,000 | $-116,537,000 | $-87,966,000 |
| Pretax Income | $-45,582,000 | $-35,753,000 | $-116,537,000 | $-87,966,000 |
| Operating Income | $-83,251,000 | $-70,577,000 | $-43,000,000 | $-39,780,000 |
| Total Operating Income As Reported | - | - | $-43,000,000 | $-88,428,000 |
| Special Income Charges | - | - | $0 | $-48,648,000 |
| Net Interest Income | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.52 | $-0.66 | $-3.74 | $-6.16 |
| Basic EPS | $-0.52 | $-0.66 | $-3.74 | $-6.16 |
| Other | ||||
| Tax Effect Of Unusual Items | $7,024,290 | $6,489,000 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-116,387,000 | $-101,118,000 | $33,585,000 | $9,241,000 |
| Total Unusual Items | $33,449,000 | $30,900,000 | $-76,211,000 | $-48,648,000 |
| Total Unusual Items Excluding Goodwill | $33,449,000 | $30,900,000 | $-76,211,000 | $-48,648,000 |
| Reconciled Depreciation | $313,000 | $359,000 | $374,000 | $373,000 |
| EBITDA (Bullshit earnings) | $-82,938,000 | $-70,218,000 | $-42,626,000 | $-39,407,000 |
| EBIT | $-83,251,000 | $-70,577,000 | $-43,000,000 | $-39,780,000 |
| Diluted Average Shares | $81,836,246 | $48,543,787 | $24,619,197 | $14,285,254 |
| Basic Average Shares | $81,836,246 | $48,543,787 | $24,619,197 | $14,285,254 |
| Diluted NI Availto Com Stockholders | $-45,617,000 | $-36,184,000 | $-116,537,000 | $-87,966,000 |
| Tax Provision | $35,000 | $431,000 | $0 | $0 |
| Gain On Sale Of Security | $33,449,000 | $30,900,000 | $-76,211,000 | - |
| Research And Development | $66,267,000 | $51,964,000 | $30,312,000 | $27,080,000 |
| Selling General And Administration | $16,984,000 | $18,613,000 | $12,688,000 | $12,700,000 |
| Other Gand A | $7,241,000 | $6,354,000 | $12,688,000 | $12,700,000 |
| Salaries And Wages | $9,743,000 | $12,259,000 | - | - |
| Impairment Of Capital Assets | - | - | $0 | $48,648,000 |
| Restructuring And Mergern Acquisition | - | - | - | - |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $48,699,000 | $30,060,000 | $-25,178,000 | $51,797,000 |
| Total Assets | $169,009,000 | $177,405,000 | $89,066,000 | $92,793,000 |
| Total Non Current Assets | $33,321,000 | $33,675,000 | $32,937,000 | $33,275,000 |
| Other Non Current Assets | $322,000 | $363,000 | $186,000 | $150,000 |
| Goodwill And Other Intangible Assets | $32,386,000 | $32,386,000 | $32,386,000 | $32,386,000 |
| Other Intangible Assets | $32,386,000 | $32,386,000 | $32,386,000 | $32,386,000 |
| Current Assets | $135,688,000 | $143,730,000 | $56,129,000 | $59,518,000 |
| Other Current Assets | $11,000 | $104,000 | $90,000 | $28,000 |
| Prepaid Assets | $1,827,000 | $2,823,000 | $4,937,000 | $3,081,000 |
| Receivables | $514,000 | $625,000 | - | - |
| Accrued Interest Receivable | $514,000 | $625,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $133,336,000 | $140,178,000 | $51,102,000 | $56,409,000 |
| Cash And Cash Equivalents | $22,808,000 | $20,549,000 | $4,612,000 | $56,409,000 |
| Cash Equivalents | - | - | - | $9,300,000 |
| Cash Financial | - | - | - | $47,109,000 |
| Debt | ||||
| Total Debt | $641,000 | $954,000 | $383,000 | $746,000 |
| Long Term Debt And Capital Lease Obligation | $283,000 | $640,000 | $0 | $383,000 |
| Current Debt And Capital Lease Obligation | $358,000 | $314,000 | $383,000 | $363,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $87,924,000 | $114,959,000 | $81,858,000 | $8,610,000 |
| Total Non Current Liabilities Net Minority Interest | $69,580,000 | $103,382,000 | $77,963,000 | $2,135,000 |
| Derivative Product Liabilities | $11,416,000 | $44,865,000 | $76,211,000 | $0 |
| Non Current Deferred Liabilities | $2,187,000 | $2,183,000 | $1,752,000 | $1,752,000 |
| Non Current Deferred Taxes Liabilities | $2,187,000 | $2,183,000 | $1,752,000 | $1,752,000 |
| Current Liabilities | $18,344,000 | $11,577,000 | $3,895,000 | $6,475,000 |
| Payables And Accrued Expenses | $13,810,000 | $9,662,000 | $1,509,000 | $4,203,000 |
| Payables | $3,627,000 | $5,833,000 | $967,000 | $2,200,000 |
| Accounts Payable | $3,627,000 | $5,833,000 | $967,000 | $2,200,000 |
| Equity | ||||
| Common Stock Equity | $81,085,000 | $62,446,000 | $-48,486,000 | $84,183,000 |
| Total Equity Gross Minority Interest | $81,085,000 | $62,446,000 | $7,208,000 | $84,183,000 |
| Stockholders Equity | $81,085,000 | $62,446,000 | $7,208,000 | $84,183,000 |
| Gains Losses Not Affecting Retained Earnings | $24,000 | $26,000 | $0 | - |
| Other Equity Adjustments | $24,000 | $26,000 | - | - |
| Retained Earnings | $-401,203,000 | $-355,586,000 | $-319,402,000 | $-202,865,000 |
| Preferred Securities Outside Stock Equity | $55,694,000 | $55,694,000 | - | - |
| Preferred Stock Equity | - | $55,694,000 | $55,694,000 | - |
| Other | ||||
| Ordinary Shares Number | $75,430,033 | $59,789,275 | $24,213,130 | $13,776,788 |
| Share Issued | $75,430,033 | $59,789,275 | $24,213,130 | $13,776,788 |
| Tangible Book Value | $48,699,000 | $30,060,000 | $-80,872,000 | $51,797,000 |
| Invested Capital | $81,085,000 | $62,446,000 | $-48,486,000 | $84,183,000 |
| Working Capital | $117,344,000 | $132,153,000 | $52,234,000 | $53,043,000 |
| Capital Lease Obligations | $641,000 | $954,000 | $383,000 | $746,000 |
| Total Capitalization | $81,085,000 | $62,446,000 | $7,208,000 | $84,183,000 |
| Additional Paid In Capital | $482,189,000 | $417,946,000 | $270,892,000 | $287,034,000 |
| Capital Stock | $75,000 | $60,000 | $55,718,000 | $14,000 |
| Common Stock | $75,000 | $60,000 | $24,000 | $14,000 |
| Long Term Capital Lease Obligation | $283,000 | $640,000 | $0 | $383,000 |
| Current Capital Lease Obligation | $358,000 | $314,000 | $383,000 | $363,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,176,000 | $1,601,000 | $2,003,000 | $1,909,000 |
| Current Accrued Expenses | $10,183,000 | $3,829,000 | $542,000 | $2,003,000 |
| Net PPE | $613,000 | $926,000 | $365,000 | $739,000 |
| Gross PPE | $613,000 | $926,000 | $365,000 | $739,000 |
| Buildings And Improvements | $613,000 | $926,000 | $365,000 | $739,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $110,528,000 | $119,629,000 | $46,490,000 | $0 |
| Preferred Stock | - | $55,694,000 | $55,694,000 | $0 |
| Other Properties | - | - | $365,000 | $739,000 |
| Goodwill | - | - | - | $0 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-62,341,000 | $-47,271,000 | $-39,527,000 | $-28,424,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-62,341,000 | $-47,271,000 | $-39,527,000 | $-28,424,000 |
| Cash Flow From Continuing Operating Activities | $-62,341,000 | $-47,271,000 | $-39,527,000 | $-28,424,000 |
| Operating Gains Losses | $-33,449,000 | $-30,900,000 | $76,211,000 | - |
| Investing Activities | ||||
| Investing Cash Flow | $10,793,000 | $-70,314,000 | $-45,287,000 | $0 |
| Cash Flow From Continuing Investing Activities | $10,793,000 | $-70,314,000 | $-45,287,000 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $53,577,000 | $133,307,000 | $33,017,000 | $0 |
| Financing Cash Flow | $53,807,000 | $133,522,000 | $33,017,000 | $0 |
| Cash Flow From Continuing Financing Activities | $53,807,000 | $133,522,000 | $33,017,000 | $0 |
| Net Common Stock Issuance | $53,577,000 | $133,307,000 | $33,017,000 | $0 |
| Common Stock Issuance | $53,577,000 | $133,307,000 | $33,017,000 | $0 |
| Net Other Financing Charges | - | - | - | - |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $22,808,000 | $20,549,000 | $4,612,000 | $56,409,000 |
| Beginning Cash Position | $20,549,000 | $4,612,000 | $56,409,000 | $84,833,000 |
| Changes In Cash | $2,259,000 | $15,937,000 | $-51,797,000 | $-28,424,000 |
| Proceeds From Stock Option Exercised | $230,000 | $215,000 | $0 | $0 |
| Net Investment Purchase And Sale | $10,793,000 | $-70,314,000 | $-45,287,000 | $0 |
| Sale Of Investment | $171,925,000 | $85,817,000 | $33,000,000 | $0 |
| Purchase Of Investment | $-161,132,000 | $-156,131,000 | $-78,287,000 | $0 |
| Change In Working Capital | $7,652,000 | $8,710,000 | $-4,917,000 | $2,368,000 |
| Change In Other Current Liabilities | $-313,000 | $-339,000 | $-363,000 | $-367,000 |
| Change In Payables And Accrued Expense | $6,724,000 | $7,751,000 | $-2,600,000 | $2,081,000 |
| Change In Payable | $6,724,000 | $7,751,000 | $-2,600,000 | $2,081,000 |
| Change In Account Payable | $6,724,000 | $7,751,000 | $-2,600,000 | $2,081,000 |
| Change In Prepaid Assets | $1,241,000 | $1,298,000 | $-1,954,000 | $654,000 |
| Stock Based Compensation | $10,451,000 | $13,122,000 | $6,545,000 | $8,153,000 |
| Amortization Of Securities | $-1,696,000 | $-2,799,000 | $-1,203,000 | $0 |
| Deferred Tax | $5,000 | $431,000 | $0 | $0 |
| Deferred Income Tax | $5,000 | $431,000 | $0 | $0 |
| Depreciation Amortization Depletion | $313,000 | $359,000 | $374,000 | $373,000 |
| Depreciation And Amortization | $313,000 | $359,000 | $374,000 | $373,000 |
| Depreciation | $313,000 | $359,000 | $374,000 | $373,000 |
| Gain Loss On Investment Securities | $-33,449,000 | $-30,900,000 | $76,211,000 | - |
| Net Income From Continuing Operations | $-45,617,000 | $-36,184,000 | $-116,537,000 | $-87,966,000 |
| Other Non Cash Items | - | $-10,000 | - | - |
| Asset Impairment Charge | - | - | $0 | $48,648,000 |
| Net Business Purchase And Sale | - | - | - | - |
| Sale Of Business | - | - | - | - |
Fetched: 2026-06-20